Rudolf Jaenisch at MIT to Speak at Stem Cell Summit – Apr 2013 in Boston, MA

Boston, MA, February 19, 2013 --(PR.com)-- Rudolf Jaenisch, founding member of the Whitehead Institute and professor of biology at the Massachusetts Institute of Technology will give a plenary keynote presentation on “ES Cells, iPS Cells & Personalized Medicine: Potential & Technical Challenges” at GTC’s Stem Cell Summit 2013 (Apr 29-30, 2013 in Boston, MA).

Rudolf Jaenisch is a pioneer of transgenic science, in which an animal’s genetic makeup is altered. Jaenisch has focused on creating transgenic mice to study cancer and neurological diseases. Jaenisch’s first breakthrough occurred in 1974 when he and Beatrice Mintz showed that foreign DNA could be integrated into the DNA of early mouse embryos. They injected retrovirus into early mouse embryos and showed that leukemia DNA sequences had integrated the mouse genome and also to its offspring. These mice were the first transgenic mammals in history.

Dr. Jaenisch will join other top experts from academia, industry and government to discuss recent developments in stem cell research. Experts will discuss pre-clinical and clinical trials of stem cell therapy, regenerative medicine, tissue engineering, cancer stem cells, stem cell reprogramming, new paradigms for drug discovery/cell therapy and regulatory policies. Experts will also discuss other important stem cell issues such business opportunities, challenges in commercialization and the potential strategies for overcoming these challenges. What categories of companies are currently commercially viable? How are they being funded? What kind of strategic relationships are available within the industry?

The Stem Cell Summit 2013 includes two concurrent tracks including a few joint sessions. This summit provides cutting-edge information on developments in all areas of stem cell research including the biology, medicine, applications, regulations, and the business of stem cells.

Track A: Stem Cell Research & Regenerative Medicine:
Joint Session: Funding Opportunities
Joint Session: Regulatory Guidance & Updates
Session: Advances in iPS & ES Cells
Session: Advances in Adult Stem Cells
Session: New Paradigms for Cell Therapy

Track B: Stem Cell Commercialization & Partnering:
Joint Session: Funding Opportunities
Joint Session: Regulatory Guidance & Update
Session: Novel Technologies in Stem Cell Research
Session: Overcoming Challenges in Clinical Development
Session: Commercialization: Bringing Therapeutics to Market
Session: Partnerships & Acquisitions

Summit Agenda: www.gtcbio.com/stemcellsummit/agenda
Summit Speaker List: www.gtcbio.com/stemcellsummit/speakers
For more information, please visit www.gtcbio.com